CureVac (NASDAQ:CVAC)

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 5 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 5 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 6 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 6 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 1 year 7 months ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 1 year 7 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 1 year 7 months ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 1 year 7 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 1 year 7 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 7 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Published on 05/01/2026 at 22:30, 1 hour 25 minutes ago

Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 1 hour 25 minutes ago

Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 1 hour 25 minutes ago

Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.
Published on 05/01/2026 at 18:00, 5 hours 55 minutes ago

Star Copper to Present at the Emerging Growth Conference on May 7, 2026
Published on 05/01/2026 at 15:35, 8 hours 20 minutes ago

LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement

View all ACCESSWIRE

Published on 05/01/2026 at 19:23, 4 hours 32 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 5 hours 15 minutes ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 6 hours 8 minutes ago

Key Figures 30.04.2026
Published on 05/01/2026 at 17:45, 6 hours 10 minutes ago

Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 6 hours 34 minutes ago

Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares

View all EQS

Published on 04/30/2026 at 20:00, 1 day 3 hours ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 4 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 4 hours ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 5 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 1 day 5 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News